retatrutide diabetes trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Phase 2 Trial of Retatrutide
Description
doi: 10.1194/jlr.R049437
What took decades with semaglutide now happens in months
This implies they are finding synergies from bringing Paperspace GPU cloud capabilities in-house and managing spend
Interest remains high (another 14% would like to)
49 Currently, there are no approved treatments with agents of this class in NASH patients
Understanding your genetic predispositions and biomarker profile before initiating compounded GLP-1 therapy can support a more targeted conversation with your provider about hydration strategies, monitoring frequency, and whether your specific risk factors warrant dietary or supplemental interventions to minimize kidney stone risk
